Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2001
To the Editor: Dr Kahn and colleagues1 claimed that after a disagreement between them and the sponsor, they published the incomplete, although generally negative, results of a trial of an immunologic modifier (Remune; The Immune Response Corp [IRC], Carlsbad, Calif) for human immunodeficiency virus (HIV) "to fulfill our responsibility to inform patients of the outcome of this study, and to contribute to their understanding of HIV-1 Immunogen if it was to be studied in another clinical trial." I find that the article is inconclusive for several reasons.
Dat NV. Outcomes of a Trial of HIV-1 Immunogen in Patients With HIV Infection. JAMA. 2001;285(17):2191-2195. doi:10.1001/jama.285.17.2191